94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1570017
This article is part of the Research Topic Targets in Cardio-Oncology: Drug Effects and Mechanisms of Action View all 10 articles
Carfilzomib in Multiple Myeloma: Unraveling Cardiac Toxicities -From Mechanisms to Diagnosis and Management
Provisionally accepted- 1 Department of cardiology, China-Japan Union Hospital, Jilin University, Changchun, China
- 2 Department of hematology, China-Japan Union Hospital, Jilin University, Changchun, China
The survival rates of patients with hematological malignancies such as multiple myeloma have improved with advances in cancer treatment. However, the risk of cardiovascular disease associated with novel therapeutic agents, including proteasome inhibitors (PIs), is becoming increasingly evident. PIs act on proteasome peptidases, leading to cell cycle arrest or apoptosis. Carfilzomib (CFZ), an intravenously administered irreversible PI, exhibits pronounced cardiovascular toxicity that is characterized by heart failure, hypertension, arrhythmia, and ischemic heart disease (IHD). This review focuses on CFZ, details its applications in treating multiple myeloma, presents its potential mechanisms of cardiotoxicity and the incidence of cardiotoxic events, and provides recommendations for the evaluation and management of adverse cardiac events during the early treatment of patients with this drug
Keywords: Carfilzomib, Cardiac toxicities, Multiple Myeloma, Proteasome inhibitor, Cardiooncology
Received: 03 Feb 2025; Accepted: 10 Mar 2025.
Copyright: © 2025 Gao, Zhou, Bai, Wang, Wang and Bi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lintao Bi, Department of hematology, China-Japan Union Hospital, Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.